RT @VPrasadMDMPH: @RahulBanerjeeMD You are upset about a tweet that says you should have gotten paid more for that year. 🤣 & toss in some a…
@RahulBanerjeeMD You are upset about a tweet that says you should have gotten paid more for that year. 🤣 & toss in some ad hominem. You even wrote a couple of those papers that didn't contribute to public heath! https://t.co/nM2QAtxuLc
RT @VPrasadMDMPH: Last year in nature reviews clinical oncology, we imagined this very thing There's a lot you can do 👇👇 https://t.co/nM2…
RT @VPrasadMDMPH: Last year in nature reviews clinical oncology, we imagined this very thing There's a lot you can do 👇👇 https://t.co/nM2…
RT @VPrasadMDMPH: Last year in nature reviews clinical oncology, we imagined this very thing There's a lot you can do 👇👇 https://t.co/nM2…
Last year in nature reviews clinical oncology, we imagined this very thing There's a lot you can do 👇👇 https://t.co/nM2QAtOxNc
Prob a very naive q, but is there a way to include a standard set of pt info for all studies w/in a disease? I guess what's "standard" would have to be dynamic as knowledge changes. But always incl renal insf, HR genetics, t11;14, & other common find
RT @RahulBanerjeeMD: 👇 Helpful read & summary by @ManniMD1 re: renal insufficiency being unreported (or more generally excluded) from #mmsm…
👇 Helpful read & summary by @ManniMD1 re: renal insufficiency being unreported (or more generally excluded) from #mmsm RCTs. Real problem especially for RRMM with no SOC CAR-T therapies yet... CC'ing @VPrasadMDMPH who mentored me on a possible solutio
RT @VPrasadMDMPH: It was terrific to move to UCSF this year (in May) - despite the state of the world Here, I met @RahulBanerjeeMD and we…
It was terrific to move to UCSF this year (in May) - despite the state of the world Here, I met @RahulBanerjeeMD and we did 2 papers together, and some cool ones forthcoming Rahul is a star myeloma/ car-t guru https://t.co/BAiYq1mWfu and https://t.co/nM2
Totally agree. Here is one way to do this https://t.co/nM2QAtOxNc
@Alexmenter @DrCraigGedye Totally agree We think this is a way to do it https://t.co/nM2QAtOxNc
RT @VPrasadMDMPH: Just out! Led by @RahulBanerjeeMD 👇 We try to solve 3 problems w/ 1 study design 1. Do drugs work in folks typically no…
RT @Isabelalor2015: This discrepancy might explain the efficacy–effectiveness gap, whereby the efficacy of cancer therapies in RCTs often e…
RT @Isabelalor2015: This discrepancy might explain the efficacy–effectiveness gap, whereby the efficacy of cancer therapies in RCTs often e…
'how future RCTs in oncology[MANY AREAS] should look: easier for frontline oncologists [CLINICIANS} to operationalize; easier for real-world patients to join; and easier for the public to extrapolate results from'
RT @TobyRichardsUWA: Clinical Trials - Go Big go Simple! I think @VPrasadMDMPH should have been a surgeon @IDEALCollab https://t.co/bjWwvPx…
Clinical Trials - Go Big go Simple! I think @VPrasadMDMPH should have been a surgeon @IDEALCollab https://t.co/bjWwvPxr6m
RT @Isabelalor2015: This discrepancy might explain the efficacy–effectiveness gap, whereby the efficacy of cancer therapies in RCTs often e…
RT @Isabelalor2015: This discrepancy might explain the efficacy–effectiveness gap, whereby the efficacy of cancer therapies in RCTs often e…
This discrepancy might explain the efficacy–effectiveness gap, whereby the efficacy of cancer therapies in RCTs often exceeds their corresponding effectiveness in clinical practice (...) @VPrasadMDMPH https://t.co/UUsmKjkEX9
RT @oncoblogger: Pragmatic trials with prespecified subgroups: what oncologists can learn from #COVID19 @NatRevClinOncol @VPrasadMDMPH http…
RT @NicoleKuderer: @OncoAlert Agreed w @VPrasadMDMPH #COVID19 could help make pragmatic RCTs with prespecified subgr routine to decr the co…
Pragmatic trials with prespecified subgroups: what oncologists can learn from #COVID19 @NatRevClinOncol @VPrasadMDMPH https://t.co/zqbxAHuiyt
RT @NicoleKuderer: @OncoAlert Agreed w @VPrasadMDMPH #COVID19 could help make pragmatic RCTs with prespecified subgr routine to decr the co…
Pragmatic trials with prespecified subgroups: what oncologists can learn from COVID-19 https://t.co/oGn6wUnL3y) via @RahulBanerjeeMD & @VPrasadMDMPH @Maherjane
RT @NicoleKuderer: @OncoAlert Agreed w @VPrasadMDMPH #COVID19 could help make pragmatic RCTs with prespecified subgr routine to decr the co…
RT @NicoleKuderer: @OncoAlert Agreed w @VPrasadMDMPH #COVID19 could help make pragmatic RCTs with prespecified subgr routine to decr the co…
RT @ADesaiMD: "Pragmatic trials with prespecified subgroups: what oncologists can learn from #COVID19" @NatRevClinOncol https://t.co/kUEQwG…
RT @NicoleKuderer: @OncoAlert Agreed w @VPrasadMDMPH #COVID19 could help make pragmatic RCTs with prespecified subgr routine to decr the co…
RT @ADesaiMD: "Pragmatic trials with prespecified subgroups: what oncologists can learn from #COVID19" @NatRevClinOncol https://t.co/kUEQwG…
@OncoAlert Agreed w @VPrasadMDMPH #COVID19 could help make pragmatic RCTs with prespecified subgr routine to decr the concerng efficacy-effectiveness gap in #oncology, providing data for most vulnerable patients @RahulBanerjeeMD cc @harpreet_md @gary_lyma
@OncoAlert
RT @NatRevClinOncol: New article by @RahulBanerjeeMD & @VPrasadMDMPH now live online: 'Pragmatic trials with prespecified subgroups: what o…
RT @ADesaiMD: "Pragmatic trials with prespecified subgroups: what oncologists can learn from #COVID19" @NatRevClinOncol https://t.co/kUEQwG…
RT @VPrasadMDMPH: Just out! Led by @RahulBanerjeeMD 👇 We try to solve 3 problems w/ 1 study design 1. Do drugs work in folks typically no…
RT @VPrasadMDMPH: Just out! Led by @RahulBanerjeeMD 👇 We try to solve 3 problems w/ 1 study design 1. Do drugs work in folks typically no…
RT @NatRevClinOncol: New article by @RahulBanerjeeMD & @VPrasadMDMPH now live online: 'Pragmatic trials with prespecified subgroups: what o…
RT @NatRevClinOncol: New article by @RahulBanerjeeMD & @VPrasadMDMPH now live online: 'Pragmatic trials with prespecified subgroups: what o…
RT @ADesaiMD: "Pragmatic trials with prespecified subgroups: what oncologists can learn from #COVID19" @NatRevClinOncol https://t.co/kUEQwG…
RT @VPrasadMDMPH: Just out! Led by @RahulBanerjeeMD 👇 We try to solve 3 problems w/ 1 study design 1. Do drugs work in folks typically no…
RT @ADesaiMD: "Pragmatic trials with prespecified subgroups: what oncologists can learn from #COVID19" @NatRevClinOncol https://t.co/kUEQwG…
RT @ADesaiMD: "Pragmatic trials with prespecified subgroups: what oncologists can learn from #COVID19" @NatRevClinOncol https://t.co/kUEQwG…
RT @ADesaiMD: "Pragmatic trials with prespecified subgroups: what oncologists can learn from #COVID19" @NatRevClinOncol https://t.co/kUEQwG…
RT @ADesaiMD: "Pragmatic trials with prespecified subgroups: what oncologists can learn from #COVID19" @NatRevClinOncol https://t.co/kUEQwG…
RT @ADesaiMD: "Pragmatic trials with prespecified subgroups: what oncologists can learn from #COVID19" @NatRevClinOncol https://t.co/kUEQwG…
"Pragmatic trials with prespecified subgroups: what oncologists can learn from #COVID19" @NatRevClinOncol https://t.co/kUEQwGszSf @RahulBanerjeeMD @VPrasadMDMPH make a case for #pragmatic RCTs to decrease the efficacy-effectiveness gap in #oncology @OncoAl
RT @NatRevClinOncol: New article by @RahulBanerjeeMD & @VPrasadMDMPH now live online: 'Pragmatic trials with prespecified subgroups: what o…
RT @VPrasadMDMPH: Just out! Led by @RahulBanerjeeMD 👇 We try to solve 3 problems w/ 1 study design 1. Do drugs work in folks typically no…
RT @VPrasadMDMPH: Just out! Led by @RahulBanerjeeMD 👇 We try to solve 3 problems w/ 1 study design 1. Do drugs work in folks typically no…
RT @NatRevClinOncol: New article by @RahulBanerjeeMD & @VPrasadMDMPH now live online: 'Pragmatic trials with prespecified subgroups: what o…
RT @NatRevClinOncol: New article by @RahulBanerjeeMD & @VPrasadMDMPH now live online: 'Pragmatic trials with prespecified subgroups: what o…
Just out! Led by @RahulBanerjeeMD 👇 We try to solve 3 problems w/ 1 study design 1. Do drugs work in folks typically not included in studies 2. How should expanded access programs work 3. How can trials be cheaper to run What can cancer med. learn from
New article by @RahulBanerjeeMD & @VPrasadMDMPH now live online: 'Pragmatic trials with prespecified subgroups: what oncologists can learn from COVID-19' https://t.co/dCa9xQu0wx #COVID19 #COVID19nCancer #hpeonc https://t.co/kIsxQfVaQS